Innovation
5 things we now know about plaque psoriasis
Plaque psoriasis is the most prevalent form of psoriasis, affecting millions worldwide. Johnson & Johnson is focused on developing novel therapies for chronic dermatologic diseases to address the unmet need that still exists.
Shockwave IVL: Inside the development of a game-changing technology to treat coronary and peripheral artery disease
Johnson & Johnson’s Patrick Stephens explains how innovative technology using ultrasonic acoustic pressure waves has made the treatment of certain types of cardiovascular disease easier for doctors and safer for patients.
What are alloantibodies?
Learn how Johnson & Johnson is investigating a therapy for two alloantibody-driven diseases that can affect the lives of developing fetuses and newborn babies.
5 ways Johnson & Johnson is innovating in medicines and therapies
From rare diseases to all-too-common cancers, Johnson & Johnson is on a mission to improve treatment options for people around the globe. Learn more about how the company is working to create new therapies for IBD, lung cancer, major depressive disorder, bladder cancer, myasthenia gravis and more.
Featured stories
“My company makes the medication that helped me fight multiple myeloma”
Paul Reidy, a Johnson & Johnson warehouse technician in Ireland, never imagined that an oncology therapy made at the facility where he works would help save his life.
“Our goal is a solution for every bladder cancer patient”
Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.
Juvenile myasthenia gravis: Inside one adolescent’s journey
The condition is typically diagnosed in adults, but research suggests an uptick in adolescent patients. Learn more about the rare autoantibody disease, how one teen is managing it and why Johnson & Johnson is working to improve treatment options for patients of all ages.
5 things we now know about atrial fibrillation
More than 50 million people worldwide are affected by this common type of heart arrhythmia. Learn the facts behind this heart condition, plus one patient’s diagnosis story.
Moving toward a more personalized approach to treating depression
The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.
